Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial

被引：0

作者：

Wollenberg, Andreas ^{[1
]}

Beck, Lisa ^{[2
]}

Deleuran, Mette Sondergaard ^{[3
]}

Blauvelt, Andrew ^{[4
]}

Thyssen, Jacob ^{[5
]}

de Bruin-Weller, Marjolein ^{[6
]}

Chen, Zhen ^{[7
]}

Khokhar, Faisal ^{[7
]}

Rodriguez-Marco, Ainara ^{[8
]}

Levit, Noah ^{[7
]}

机构：

[1] Ludwig Maximillian Univ, Munich, Germany

[2] Univ Rochester, Rochester, NY 14627 USA

[3] Aarhus Univ Hosp, Aarhus, Denmark

[4] OHSU, Portland, OR USA

[5] Univ Copenhagen, Copenhagen, Denmark

[6] Univ Utrecht, Med Ctr, Utrecht, Netherlands

[7] Regeneron Pharmaceut, Tarrytown, NY USA

[8] Sanofi, Paris, France

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

030

引用

页码：AB10 / AB10

页数：1